CN102727865A - Compound calcium capsule free of calcium carbonate and vitamin D - Google Patents
Compound calcium capsule free of calcium carbonate and vitamin D Download PDFInfo
- Publication number
- CN102727865A CN102727865A CN2012102426936A CN201210242693A CN102727865A CN 102727865 A CN102727865 A CN 102727865A CN 2012102426936 A CN2012102426936 A CN 2012102426936A CN 201210242693 A CN201210242693 A CN 201210242693A CN 102727865 A CN102727865 A CN 102727865A
- Authority
- CN
- China
- Prior art keywords
- calcium
- parts
- absorption
- vitamin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a compound calcium capsule free of calcium carbonate and vitamin D, which belongs to the technical field of a compound calcium preparation. The compound calcium capsule provided by the invention is prepared from raw materials by weight as follows: 120-650 parts of calcium citrate, 110-550 parts of calcium citrate malate, 25-120 parts of calcium carbonate and 10-90 parts of casein phosphopeptide. The calcium preparation provided by the invention effectively combines a calcium source with a promoter, the prescription is reasonable, the calcium content is high, the dissolubility is good, the absorption of calcium is effectively promoted, the absorption rate of the calcium is greatly increased; and using the casein phosphopeptide as the raw material is not only capable of promoting the absorption of the calcium, but also capable of promoting the absorption of divalent mineral nutrients such as ferric and zinc and the like.
Description
Technical field
The present invention relates to the compounded calcium preparation technical field, the compound calcium capsule of especially a kind of not carbonated calcium and vitamin D.
Background technology
Calcium is our Source of life, each stage in that life is grown up, all play important effect, and be the requisite important element of health.Calcium deficiency can cause a series of symptoms, osteoporosis, hyperosteogeny, osteodynia, muscle twitches; Children's's skeleton and hypoplasia of tooth, the Gou building is sick, diseases such as osteomalacia, lumbar vertebra cervical vertebra ache, lower limb are soft, cramp, weak, agitation.
Calcium deficiency is global nutrition problem; According to " Chinese residents nutrition and Health Situation " investigation report; The diet structure that Chinese are traditional lacks the high food of calcic and causes the degree of Chinese's calcium deficiency very serious, and resident's calcium intake is merely 391 milligrams, is equivalent to 41% of recommended intake.Solving the calcium deficiency problem must set about from two aspects simultaneously, and one for increasing the intake of calcium, and two for improving the absorption rate of calcium.On the domestic market more than 200 kind of calsium supplement arranged at present, be conceived to increase the intake of calcium mostly.In recent years, some nutraceutical and health food are also strengthened vitamin D when it produce to strengthen calcium, and purpose is to improve the absorption rate of calcium, and this is up to the present to solve the calcium absorption utilization rate and the only way that adopts.
Most of calcium products adopt the primary raw material of calcium carbonate as calcium replenishing, adopt forced for vitamins D to improve the absorption rate of body to calcium.Though the calcium carbonate calcium content is higher, absorbance is low, transhipment rate and utilize rate variance, and especially it is bigger to the gastric mucosa infringement, causes digestive tract, urinary stone especially easily, has become the disadvantage of generally acknowledging in the world.Vitamin D is applied as calcium promoter for many years always; But scientific research is constantly found; The prolonged application vitamin D; Not only hinder the absorption of ferrum, also intoxicating phenomenon can occur:, caused the vigilant of domestic and international medical circle and consumer like nervous symptoms, digestive tract or urinary tract infringement, anemia etc.
Summary of the invention
The present invention provides the compound calcium capsule of a kind of not carbonated calcium and vitamin D, and calcium source and promoter effectively combine, reasonable recipe, and calcium content is high, and solubility property is good, can effectively promote the absorption of calcium, improves the absorbance of calcium greatly; Adopt phosphopeptide caseinate as raw material, not only can promote the absorption of calcium, and promote the absorption of bivalence mineral nutrients such as ferrum, zinc.
The technical scheme that the present invention taked is:
The compound calcium capsule of a kind of not carbonated calcium and vitamin D is processed by the raw material of following weight parts: calcium citrate 120-650 part, calcium cirate malate 110-550 part, calcium acetate 25-120 part, phosphopeptide caseinate 10-90 part.Be preferably: calcium citrate 200-300 part, calcium cirate malate 200-300 part, calcium acetate 25-50 part, phosphopeptide caseinate 10-20 part.
Take by weighing raw material according to above-mentioned weight proportion, press every encapsulated getting final product of 0.40-0.60g behind the mixing.
Calcium citrate does not need the gastric acid activation to absorb, and absorbance is good, can not produce carbon dioxide like calcium carbonate again in vivo and cause flatulence, and is harmless to gastrointestinal mucosal.Simultaneously; Citric acid has stronger complexing to calcium, and when the concentration of citric acid increased in vivo, it can combine free calcium ion; And displacement is such as the calcium in calcium oxalate, the calcium phosphate; Form stable complex soluble in water, in body, discharge, suppressed calcium salt (calcium oxalate etc.) is separated out crystal formation calculus owing to the over-saturation state process.Especially for the patient who replenishes the calcium, calcium citrate can be replenished the calcium and can be prevented the formation of calculus such as calcium oxalate.
Calcium cirate malate is called calcium citrate malate again, is the synthetic by a certain percentage organic chelate of calcium, citric acid and malic acid.The calcium citrate malate dissolubility reduces and increases with pH value, and under alkalescence and nearly neutral environment, still has dissolubility preferably, and calcium citrate malate is at the highly dissoluble of broad pH value scope.Calcium citrate malate constituent citric acid and malic acid have the left-handed structure of optics; And be the mesostate of tricarboxylic acid cycle in the body; Can guarantee to slowly release calcium ion with citric acid and malic acid oxidation in vivo, this characteristic has just caused calcium citrate malate to have high biology of absorbing property.
2-3 other atoms owing to generally be separated by between two coordination atoms of calcium citrate malate, so that it is central ion forms stable pentatomic ring or six atom cycloalkyl structures, stable far beyond simple complex; Its speed that discharges calcium ion is comparatively slow; Though the patient for being badly in need of replenishing the calcium can not reach the purpose of replenishing the calcium fast, the performance of its slow releasing function continues to keep the calcium ion concentration meaning very big to balanced in the body; Reasonably combined with calcium citrate and calcium acetate, play good addendum effect.
The calcium acetate the active calcium ion content is high, and solubility property is strong in water and gastric juice, and all ionizings need not the gastric acid decomposition, can directly be absorbed by the body, and has the advantages that the active calcium ion content height, solubility property are good, replenish the calcium rapidly.It is neutral that the aqueous solution of calcium acetate is, and stomach, intestinal do not have sense of discomfort after taking.The calcium acetate solubility property is good, replenish the calcium rapidly, remedied calcium citrate malate and replenished the calcium not enoughly comparatively slowly, and calcium acetate does not have the risk that increases renal calculus to normal population simultaneously.
Phosphopeptide caseinate (CPP) is present internationally recognized efficient calcium ferrum absorption enhancer, and CPP ability chelating calcium, ferrum, zinc ion protect it not precipitated by aniones such as the phosphoric acid in the meals, oxalic acid, phytic acid; Suppress the generation of infusible precipitate; Avoid the loss of calcium, ferrum, zinc, final because of the passive absorption of the raising of free calcium concentration, not only promote calcium absorption; Also can promote the absorption of bivalence mineral nutrients such as ferrum, zinc, and this greatest drawback of calcium carbonate and vitamin D combination exactly.CPP is safety not only, and can promote calcium citrate, calcium cirate malate, calcium acetate better to absorb and utilize, and effect of supplemented calcium is apparently higher than the original combined of calcium carbonate and vitamin D.
In the prescription, its stronger complexing of calcium citrate performance with the calcium ion complexation, prevents the equimolecular supersaturation of calcium oxalate, thereby suppresses the formation of renal calculus.Calcium cirate malate, calcium acetate be safety not only, also has distinctive feature aspect absorbing, utilizing, and with the calcium citrate combination effect of maximizing favourable factors and minimizing unfavourable ones, having complementary advantages is arranged more.
Adopt the beneficial effect that technique scheme produced to be:
1. calcium source and promoter effectively combine, reasonable recipe, and calcium content is high, and solubility property is good, can effectively promote the absorption of calcium, improves the absorbance of calcium greatly.
2. adopt phosphopeptide caseinate as raw material, not only can promote the absorption of calcium, and promote the absorption of bivalence mineral nutrients such as ferrum, zinc.
One, contrast test
Be checking product effect; We are that raw material has been developed calcium preparation capsule of the present invention with calcium citrate, calcium cirate malate, calcium acetate, phosphopeptide caseinate (CPP); And it has been carried out the dissolution comparative measurements with 3 kinds of calcium preparation at present commonly used at different dissolution mediums, the result reports as follows.
1 instrument, reagent and reagent
Intelligence stripping experiment instrument
Acidometer
Zinc oxide (volumetric(al) standards)
Hydrochloric acid (analytical pure)
Calcium preparation capsule of the present invention (500mg/ grain, self-control, lot number: 110625)
Calcium dimension D capsule (the 250mg/ grain, commercially available, lot number: 110502)
Calcium carbonate tablet (the 500mg/ sheet, commercially available, lot number: 1104167)
The calcareacarbonica sheet (the 250mg/ sheet, commercially available, lot number: 110510)
2 methods and result
2. 1 calcium content assay method
The assay of calcium all adopts Chinese Pharmacopoeia (2010 editions) EDTA titrimetry to measure, and selecting calconum for use is that indicator is measured.
2. 2 dissolution determinations
Dissolution medium adopts distilled water, pH=2 dilute hydrochloric acid solution, simulated gastric fluid and pH=5 dilute hydrochloric acid solution respectively.Mensuration is operated according to Chinese Pharmacopoeia (2010 editions) dissolution method.Get above-mentioned medium 900ml, heating makes solution temperature remain on 37 ℃ ± 0. 5 ℃, regulates rotating speed and makes it stabilize to 100rmin-1.6 of sample thiefs are put respectively and are changeed in the basket, in accordance with the law operation.Through 45min, filter in right amount in regulation sample point draw solution, get subsequent filtrate, measure according to 2. 1 calcium content algoscopys.Get 6 meansigma methodss, calculate 4 kinds of calcium tablets dissolution in 4 kinds of media respectively, the result sees table 1.
Several kinds of calcium tablets of table 1 dissolution in different solvent media compares
Can find out from table 1, be 58.5% with calcium preparation of the present invention dissolution in distilled water, and low acid is 95.1%; Normal gastric acid reaches 96.7%, and peracid is 100%, all is higher than other products of replenishing the calcium; Show that calcium preparation dissolution of the present invention is better, more help absorption of human body, suitable crowd is wider.
Two, multiple calcium preparation such as calcium preparation of the present invention is to the rat bone metabolic effect
For inquiring into calcium preparation of the present invention to the rat bone metabolic effect; This experiment selected 4 all SD rats are subjects; Give its compounded calcium preparation and several kinds of calcium preparation commonly used; Measure the representative index of reflection bone metabolism functions such as rat bone density (BMD), bone calcium and serum alkaline phosphatase (ALP), the observation different calcium agent is to the animal bone metabolic effect.
1 materials and methods
1.1 material
1.1.1 animal feed adds calcium preparation calcium preparation of the present invention, calcium citrate, calcium citrate malate, calcium acetate and calcium carbonate.Calcium content is respectively 20%, 21%, 23%, 22.7%, 40%.
1.1.2 the healthy SD ablactation in 4 ages in week of experimental animal cleaning level rat, female, 66, body weight 60～75g is provided by the department of the Chinese Academy of Sciences of Department Of Medicine, Peking University's laboratory animal section.Laboratory animal production licence: SCXK (capital) 2006-0008.Animal occupancy permit: SYXK (capital) 2006-0025.Feeding environment is the barrier level, 20～24 ℃ of experimental situation temperature, humidity 54%～58%.
1.1.3 animal normal feedstuff animal normal feedstuff prescription is 10.0% casein, 15.0% analysis for soybean powder, 54.0% Semen Tritici aestivi flour; 4.0% Semen Maydis oil or Oleum Arachidis hypogaeae semen, 2.0% cellulose, 2.6% mixed mineral salt; 1.0% mixed vitamin, 0.2% choline chloride, 0.2%DL-methionine; 11.0% starch, the adjustment calcium content is the 150mg/100g feedstuff.With this low each animal subject group of calcium prescription forage feed.Institute of Experimental Animals, Chinese Academy of Medical Sciences provides, production licence number: SCXK (capital) 2006-0003.
1.2 test method
1.2.1 after animal divides into groups and dosage is provided with the animal via adaptability and fed for 1 week, weigh, be divided into 6 groups by body weight subregion randomized blocks, 11 every group.5 times (press the 60kg weighing machine, then dosage is calcium 41.7mg/kgBW) with human calcium's supplement recommended intake (calcium 500mg/d) are each animal subject group calcium intake, establish a low calcium matched group with basis low calcium prescription forage feed.Calcium preparation content and calcium content that test is respectively organized in the feedstuff are as shown in table 2.
Table 2 different calcium agent calcium content (mg/100g) in content and the feedstuff in feedstuff
1.2.2 calcium preparation gives and the cycle by animal food ration 10%, respectively 5 kinds of calcium preparation are mixed in the feedstuff, the group laboratory animal is equal freely ingests for all, drinks deionized water, raise to 13 weekend femoral artery get blood and cut open inspection.
1.2.3 observation index and method
(1) BMD measures: measure rats with left femur mid point, distal end and proximal part BMD with dual intensity X line absorption borne densitometers (DEXA).
(2) calcium content of bone is measured: plasma emission spectrometer (ICP-AES) is measured the right lateral thigh calcium content of bone.
(3) serum levels of ALP assay: the p-nitrophenylphosphate method is measured the content of ALP in the serum.
2 results and analysis
Calcium citrate group and calcium carbonate components do not have 1 rat state not good enough and be slow in action, weight loss, remove in the 8th week of experiment.Do not see obviously unusual during other group zooperies.
2.1 different calcium agent is to the influence of rat BMD
Respectively with low calcium matched group, calcium carbonate group femur distal end BMD relatively, the bone density of calcium preparation group of the present invention, calcium citrate malate group and calcium acetate group increases, and significant difference (P < 0.05) is arranged.At femur stage casing and proximal part, the difference of bone density does not have statistical significance between each group, and different calcium agent is seen table 3 to the influence of rat BMD.
Table 3 different calcium agent is to the influence (
± s) of rat BMD
#: comparing difference with low calcium matched group has significance (P < 0.05)
*: comparing difference with calcium carbonate control group has significance (P < 0.05)
2.2 different calcium agent is to the influence of rat bone calcium content
Respectively with low calcium matched group, calcium carbonate group calcium content of bone relatively, calcium preparation group calcium content of bone of the present invention increases, difference has statistical significance (P < 0.05), different calcium agent is seen table 4 to the influence of rat bone calcium content.
Table 4 different calcium agent is to the influence (
± s) of rat bone calcium content
#: comparing difference with low calcium matched group has significance (P < 0.05)
*: comparing difference with calcium carbonate control group has significance (P < 0.05)
2.3 different calcium agent is to the influence of rat blood serum ALP
Compare with low calcium matched group, the serum ALP activity unit of calcium preparation group rat of the present invention reduces, and difference has statistical significance (P < 0.05), and correction data is seen table 5.
Table 5 different calcium agent is to the influence (
± s) of rat blood serum ALP
#: comparing difference with low calcium matched group has significance (P < 0.05)
3 discuss
BMD is a most frequently used index of estimating body calcium nutritional status, and World Health Organization (WHO) measures BMD as the recommendation index of estimating bone loss.In this research, the femur distal end BMD of calcium preparation group of the present invention, calcium citrate malate group and calcium acetate group increases (P < 0.05) than calcium carbonate group and low calcium matched group respectively.The femur stage casing is main with cortical bone mainly, and the proximal part of femur and distal end are main with spongy bone mainly.There are some researches show that it is main position that the minimizing of bone amount mainly occurs in spongy bone, and be that the suffered influence in main position is less with the cortical bone.It is main femur two ends that the fracture of old people's femur also often occurs in spongy bone.This shows, effectively replenishes the calcium and can reduce the risk of fractures degree.
Bone is also referred to as " calcium storehouse ", and osseous tissue has stored the body calcium of body more than 99%.Blood calcium concentration is crossed when hanging down, and body will mobilize the calcium in the skeleton to go into blood, so bone calcium is one of important indicator of reflection body calcium nutriture.In test group, calcium preparation group rat femur calcium content of the present invention is higher than calcium carbonate control group (P < 0.05), and the difference of other each test group and calcium carbonate control group does not all have statistical significance.
The bone metabolism mark be a kind of reflect bone formation, absorbing state and be present in blood, urine in material.Can reflect the bone metabolism state of measuring moment through the bone metabolism mark of measuring in blood sample and the urine sample.During calcium deficiency, often cause that alkaline phosphatase activities raises.Result of study shows, ALP active unit is higher than calcium carbonate control group (P < 0.05) in the calcium preparation group rat blood serum of the present invention.This prompting calcium preparation group of the present invention is better by the effect that the animal body utilizes.
Comprehensive above each item bone metabolism index, calcium preparation of the present invention for SD rat bone metabolic function have promote preferably and the effect of improvement effect, especially BMD and these 2 key indexs of calcium content of bone better.Possibly be that effect of supplemented calcium is remarkable, and is non-stimulated to gastrointestinal mucosal, can not cause significant advantages such as calculus because calcium citrate, calcium citrate malate and calcium acetate all have the absorption rate height.Simultaneously, phosphopeptide caseinate (CPP) is present internationally recognized efficient calcium ferrum absorption enhancer, not only safety and can promote calcium citrate, calcium citrate malate and calcium acetate better to absorb and utilize.So calcium preparation of the present invention can be used as the better selection of calcium complement agent.
The specific embodiment
Embodiment 1
Take by weighing raw material by following weight ratio: 120 parts of calcium citrates, 550 parts of calcium cirate malate, 50 parts of calcium acetates, 90 parts of phosphopeptide caseinates, with encapsulated behind the above-mentioned raw materials mixing by every 0.45g.
Embodiment 2
Take by weighing raw material by following weight ratio: 300 parts of calcium citrates, 353 parts of calcium cirate malate, 25 parts of calcium acetates, 10 parts of phosphopeptide caseinates, with encapsulated behind the above-mentioned raw materials mixing by every 0.55g.
Embodiment 3
Take by weighing raw material by following weight ratio: 500 parts of calcium citrates, 201 parts of calcium cirate malate, 70 parts of calcium acetates, 50 parts of phosphopeptide caseinates, with encapsulated behind the above-mentioned raw materials mixing by every 0.6g.
Embodiment 4
Take by weighing raw material by following weight ratio: 650 parts of calcium citrates, 110 parts of calcium cirate malate, 120 parts of calcium acetates, 20 parts of phosphopeptide caseinates, with encapsulated behind the above-mentioned raw materials mixing by every 0.45g.
Embodiment 5
Take by weighing raw material by following weight ratio: 260 parts of calcium citrates, 253 parts of calcium cirate malate, 27 parts of calcium acetates, 10 parts of phosphopeptide caseinates, with encapsulated behind the above-mentioned raw materials mixing by every 0.40g.
Embodiment 6
Take by weighing raw material by following weight ratio: 200 parts of calcium citrates, 300 parts of calcium cirate malate, 50 parts of calcium acetates, 90 parts of phosphopeptide caseinates, with encapsulated behind the above-mentioned raw materials mixing by every 0.55g.
Claims (2)
1. the compound calcium capsule of carbonated calcium and vitamin D not is characterized in that being processed by the raw material of following weight parts: calcium citrate 120-650 part, calcium cirate malate 110-550 part, calcium acetate 25-120 part, phosphopeptide caseinate 10-90 part.
2. the compound calcium capsule of a kind of not carbonated calcium according to claim 1 and vitamin D is characterized in that being processed by the raw material of following weight parts: calcium citrate 200-300 part, calcium cirate malate 200-300 part, calcium acetate 25-50 part, phosphopeptide caseinate 10-20 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102426936A CN102727865A (en) | 2012-07-13 | 2012-07-13 | Compound calcium capsule free of calcium carbonate and vitamin D |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102426936A CN102727865A (en) | 2012-07-13 | 2012-07-13 | Compound calcium capsule free of calcium carbonate and vitamin D |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102727865A true CN102727865A (en) | 2012-10-17 |
Family
ID=46984629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102426936A Pending CN102727865A (en) | 2012-07-13 | 2012-07-13 | Compound calcium capsule free of calcium carbonate and vitamin D |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727865A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288579A (en) * | 2015-11-14 | 2016-02-03 | 河北御芝林药业有限公司 | Calcium supplement agent and preparation method thereof |
| CN108853516A (en) * | 2018-07-07 | 2018-11-23 | 成都迈德克科技有限公司 | A kind of functional load medicine calcium citrate |
| CN114642647A (en) * | 2020-12-19 | 2022-06-21 | 江苏雅博动物健康科技有限责任公司 | Liquid calcium soft capsule and preparation method thereof |
| CN114885890A (en) * | 2022-04-21 | 2022-08-12 | 扬州大学 | Method for improving egg quality of laying hens in later period of egg laying |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1242985A (en) * | 1999-07-26 | 2000-02-02 | 李久成 | Compounded calcium preparation, preparing method and use thereof |
| CN1748571A (en) * | 2005-10-13 | 2006-03-22 | 杭州康源食品科技有限公司 | Calcium supplementing health food base materials |
| CN101288686A (en) * | 2008-05-15 | 2008-10-22 | 江西本草天工科技有限责任公司 | Health preparation for increasing bone density and preparation method thereof |
-
2012
- 2012-07-13 CN CN2012102426936A patent/CN102727865A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1242985A (en) * | 1999-07-26 | 2000-02-02 | 李久成 | Compounded calcium preparation, preparing method and use thereof |
| CN1748571A (en) * | 2005-10-13 | 2006-03-22 | 杭州康源食品科技有限公司 | Calcium supplementing health food base materials |
| CN101288686A (en) * | 2008-05-15 | 2008-10-22 | 江西本草天工科技有限责任公司 | Health preparation for increasing bone density and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288579A (en) * | 2015-11-14 | 2016-02-03 | 河北御芝林药业有限公司 | Calcium supplement agent and preparation method thereof |
| CN108853516A (en) * | 2018-07-07 | 2018-11-23 | 成都迈德克科技有限公司 | A kind of functional load medicine calcium citrate |
| CN108853516B (en) * | 2018-07-07 | 2023-01-06 | 成都迈德克科技有限公司 | Functional medicine-carrying calcium citrate |
| CN114642647A (en) * | 2020-12-19 | 2022-06-21 | 江苏雅博动物健康科技有限责任公司 | Liquid calcium soft capsule and preparation method thereof |
| CN114885890A (en) * | 2022-04-21 | 2022-08-12 | 扬州大学 | Method for improving egg quality of laying hens in later period of egg laying |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106420643B (en) | A kind of chewable tablets and preparation method thereof containing vitamine C sodium | |
| CN104068306B (en) | Health food for improving bone density and preparation method of health food | |
| CN102028139B (en) | Calcium tablet easy to assimilate | |
| CN108783467B (en) | Composition for improving osteoporosis and increasing bone density and preparation method thereof | |
| CN102415447B (en) | Calcium supplement electuary for infants and preparation process thereof | |
| KR101577083B1 (en) | Formulas comprising calcium, magnesium, zinc, and vitamine D3 for the prevention and amelioration of osteoporosis | |
| CN103083648A (en) | Troche for enhancing bone mineral density based on milk mineral salt as raw material as well as preparation method thereof | |
| CN102727865A (en) | Compound calcium capsule free of calcium carbonate and vitamin D | |
| CN105288579A (en) | Calcium supplement agent and preparation method thereof | |
| CN104906136A (en) | Multivitamin composition | |
| Huo et al. | Preparation and biological efficacy of haddock bone calcium tablets | |
| CN107319242A (en) | L-cn effervescent tablet for slimming and preparation method thereof | |
| CN105581331A (en) | Calcium supplementing nutrition composition | |
| CN102613559A (en) | Composite protein powder capsule and preparation method thereof | |
| JP2007022992A (en) | Preparation for hyperphosphatemia, and food, drink or feed containing the same | |
| CN108669403A (en) | A kind of multivitamin effervescent tablet of iron content zinc calcium and its annular preparation and preparation method | |
| CN108936602A (en) | A kind of double protein sports tonica and preparation method thereof | |
| CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same | |
| CA2757351C (en) | Anti-mental fatigue drug | |
| CN112675194A (en) | Calcium supplement composition | |
| CN109805390A (en) | A kind of calcium nervonate, nervonic acid zinc and vitamin K2Compound composition soft capsule | |
| CN110250525A (en) | A kind of composition composition and preparation method thereof for gut purge before enteroscopy | |
| CN108552535A (en) | calcium soft capsule and preparation method | |
| CN100364969C (en) | Water soluble vitamins D2 preparation method | |
| CN103330904B (en) | Medicine used for preventing intestinal tract disease of infants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121017 |